Global BioAccess Fund
Global BioAccess Fund is a venture capital firm established in 2021 and located in New York, New York. The firm focuses on investing in transformative technologies that address significant unmet medical needs in areas such as oncology, rare diseases, central nervous system disorders, and cardiology. By providing essential capital, Global BioAccess Fund supports early-stage companies in their pursuit of Investigational New Drug submissions and clinical trials, aiming to foster innovation and advancement in the healthcare sector.
Nuvig Therapeutics
Series B in 2024
Nuvig Therapeutics is focused on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function, particularly following inflammation. The company is building a pipeline of novel immune therapeutics specifically designed for chronic inflammatory and autoimmune diseases. By leveraging natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options available to healthcare providers and improve patient outcomes.
ShiraTronics
Series B in 2024
ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.
Acesion Pharma
Series B in 2023
Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.